Jinwon Life Sciences Signs Strategic Business Partnership MOU with Aston Science
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 8th that it has signed a memorandum of understanding (MOU) to establish a strategic partnership with Aston Science, a company specializing in therapeutic cancer vaccines, for the joint research, development, and commercialization of next-generation nucleic acid-based vaccines.
A representative from GeneOne Life Science explained, "Through this MOU, the two companies will collaborate as partners in new drug development by sharing capabilities through open innovation for the joint research and development of next-generation nucleic acid-based vaccines targeting new target substances."
Through this MOU, the two companies agreed to mutually cooperate across all business areas including ▲joint research and development ▲support for preclinical and clinical development ▲production and commercialization.
GeneOne Life Science and Aston Science will prioritize sharing information on new antigen determinants for therapeutic vaccine drug research and development and conducting research to transition to mRNA-based vaccines.
Park Younggeun, CEO of GeneOne Life Science, said, "Aston Science is a client of our subsidiary VGXI, which provides high-quality plasmid DNA. Through this MOU, we will closely cooperate in both research and development and production, and we expect that this mutual cooperation will create greater synergy."
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Australia Orders Chinese Investors Out of Rare Earth Firms... China Immediately Pushes Back
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Shin Heonwoo, CEO of Aston Science, said, "We are pleased to solidify Aston Science’s expertise in cancer therapeutic vaccine research and development through the partnership with GeneOne Life Science, and to expand our next-generation nucleic acid-based vaccine R&D capabilities from plasmid DNA vaccines to mRNA vaccines. We hope that this MOU will serve as a starting point to strengthen the R&D capabilities of both companies through complementary roles and advance toward the commercialization of next-generation nucleic acid-based vaccines."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
